Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Arianna Huffington's Thrive Global partners with Zepbound-maker Eli Lilly to share content on healthy habits where patients ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...